Global investment firm Bain Capital has launched its first dedicated life sciences fund.
According to a regulatory form filed with the SEC, the vehicle is called Bain Capital Life Sciences Fund, L.P.
The document lists Boston-based Managing Directors Adam M. Koppel, MD, PhD, and Jeffrey Schwartz as people related to the offering, whose targeted amount was not disclosed.
With more than $75 billion of assets under management, Bain Capital, LP, is one of the world’s leading private multi-asset alternative investment firms. Founded in 1984, the firm operates in several asset classes including private equity, credit, public equity and venture capital.